Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases. Founded in 1998, it focuses on innovative human antibody technologies to create differentiated products that address unmet medical needs in oncology and beyond. Key marketed products include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and other B-cell malignancies; and Tivdak for recurrent or metastatic cervical cancer post-chemotherapy. The company also generates significant royalties from partnerships, notably DARZALEX for multiple myeloma, marketed by Johnson & Johnson. Genmab A/S maintains a robust pipeline with investigational candidates like epcoritamamab, rinatabart sesutecan, and others targeting solid tumors, blood cancers, and rare diseases through collaborations with AbbVie, Pfizer, and Novartis. Recently, it expanded via an $8 billion acquisition of Merus N.V., bolstering its late-stage oncology assets including petosemtamab. With over 2,600 employees, Genmab A/S plays a pivotal role in advancing precision oncology, driving revenue growth through royalties, product sales, and pipeline maturation.

Vous souhaitez comprendre comment nous évaluons la sécurité des dividendes ? Lire notre méthodologie complète